Histogenics (HSGX) Tops Q1 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Histogenics (HSGX) Tops Q1 EPS by 24c
May 14, 2015 6:30 AM EDT
WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the first quarter ended March 31, 2015. Â
"We continued to make progress toward our goal of enrolling our Phase 3 study of NeoCart® by the second quarter of 2016.  Since we completed our initial public offering in late 2014, our team has continued enhancing and executing on our clinical enrollment plans and continued scaling and technology transfer activities in our manufacturing processes," stated Adam Gridley, President and... More
